The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Original Article: FDA Approves Atezolizumab Regimen for Frontline Small Cell Lung Cancer